Search Within

Daniel C Danila

  1. "Heiko Schoder"
Formats
  1. Meeting Abstract (3)
  2. Journal Article (1)
Groups
  1. Department of Medicine (4)
  2. Genitourinary Oncology Service (4)
  3. Molecular Imaging and Therapy Service (4)
  4. Radiology, Department of (4)
  5. Solid Tumor Oncology Division (4)
  6. Sloan Kettering Institute Postdocs (3)

More Groups

People
  1. Heiko Schoder (4)
  2. Michael Morris (4)
  3. Deborah Fidele (2)
  4. Elisa De Stanchina (2)
  5. Goutam Chakraborty (2)
  6. Howard Scher (2)

More People

Years
  1. 2025 (1)
  2. 2021 (2)
  3. 2013 (1)
Publications
  1. Journal of Clinical Oncology (2)
  2. Cancer Research (1)
  3. European Urology Oncology (1)
Publishers
  1. American Society of Clinical Oncology (2)
  2. American Association for Cancer Research (1)
  3. Elsevier B.V. (1)

Results (4)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical, imaging, and technical factors associated with successful genomic profiling of bone biopsy tissue in prostate cancer
    Journal Article

    Ridouani, F.; Vargas, H. A.; Holzwanger, D. J.; Schöder, H.; Waters, E.; Petre, E. N.; Martin, A.; Satagopan, J.; Gonen, M.; Autio, K. A.; more...
    European Urology Oncology (2025)

    Fulltext@MSK | Save
  • Bcl-2 inhibitor enhances anti-androgen therapy induced regression of castration sensitive prostate cancer
    Meeting Abstract

    Hirani, R.; Nandakumar, S.; Kalidindi, T.; Fidele, D.; Rajanala, H.; Mazzu, Y.; Yoshikawa, Y.; Jehane, L.; Lee, G. S. M.; de Stanchina, E.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Significance of targeting the antiapoptotic pathway in castration-sensitive prostate cancer
    Meeting Abstract

    Chakraborty, G.; Hirani, R.; Nandakumar, S.; Kalidindi, T. M.; Fidele, D.; Rajanala, S. H.; Mazzu, Y. Z.; Yoshikawa, Y.; Jehane, L. E.; Lee, G. S. M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Evaluating 18F-16B-fluoro-5α-dihydrotestosterone (FDHT) and FDG-PET as a measure of disease progression in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Autio, K. A.; Fox, J. J.; Schneider, C. W.; Schöder, H.; Humm, J.; Rathkopf, D. E.; Slovin, S. F.; Danila, D. C.; Haupt, E. C.; Larson, S. M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save